Therapy for isocitrate dehydrogenase 2 (IDH2)^R172 -mutant acute myeloid leukaemia

Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2)^R172 -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2^WT and IDH2^R140 -mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2^R172 AML. We found an improved outcome for IDH2^R172 -mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.